论文部分内容阅读
按REAL分类法B细胞起源的弥漫性大细胞淋巴瘤可分多种形态学亚型。为探讨弥漫性大B细胞淋巴瘤(DLBCL)形态学亚型的临床特征和对治疗反应的影响,作者调研了132例初发DLBCL患者,按REAL和修正的Kiel病理分型法和免疫组织化学检验区分形态学亚型。所分析的临床指标包括:年龄、性别、Ann Arbor分期、原发性结外病变及其部位、骨髓累及、有无B组症状或大块肿瘤以及全身状况ECOG评分。实验室参数包括血清LDH和白蛋白浓度。治疗方案的选择不考虑形态学亚型,17例未治,9例姑息治疗,79例采用治愈性治疗(curative ap-proach),包括蒽环类抗生素的联合化疗(CHOP、CNOP、MACOP-B等)及巩固性放射治疗(30例,39％)。
According to the REAL classification, diffuse large cell lymphoma of B-cell origin can be divided into multiple morphological subtypes. To investigate the clinical features and treatment response of morphological subtypes of diffuse large B-cell lymphoma (DLBCL), the authors investigated 132 patients with newly diagnosed DLBCL, according to REAL and modified Kiel pathological typing and immunohistochemistry. Tests distinguish morphological subtypes. The clinical parameters analysed included: age, gender, Ann Arbor stage, primary extranodal lesions and sites, bone marrow involvement, presence or absence of group B symptoms, or mass tumors, and general condition ECOG scores. Laboratory parameters include serum LDH and albumin concentrations. Treatment options were not considered for morphological subtypes, 17 were untreated, 9 were palliative, and 79 were curative ap-proches, including anthracycline combined chemotherapy (CHOP, CNOP, MACOP-B) Etc.) and consolidating radiation therapy (30 cases, 39%).